, PRoFESS enrolled 20 332 patients from 695 centers in 35 countries who recently had an ischemic stroke. Patients with cardioembolic strokes requiring anticoagulation, known severe renal insufficiency defined as renal artery stenosis or serum creatinine >265 μmol/L (>3.0 mg/dL), were excluded.
T he relationship of low estimated glomerular filtration rate (eGFR) with recurrent stroke risk after a recent ischemic stroke has rarely been investigated. 1 Furthermore, reninangiotensin system (RAS) modulators that limit chronic kidney disease (CKD) progression, 2 and reduce vascular risk in patients with cardiac disease, independent of their blood pressure lowering, 3 have not been assessed for potential benefit in recent patients with stroke with CKD. In this study, we evaluate the association of low eGFR with recurrent stroke risk and assess whether add-on RAS modulator therapy is related to lower recurrent stroke risk among patients with stroke with low eGFR.
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Results
Of the 20 332 subjects enrolled in Table I in the onlineonly Data Supplement. Patients with CKD were more likely to be older, women, with a baseline history of hypertension, coronary artery disease, symptomatic cerebrovascular disease, antihypertensive drug use, and less likely to be smokers. Absolute risks of recurrent vascular events by baseline eGFR were consistently worse among patients with PRoFESS with low eGFR (Table II in the online-only Data Supplement), and CKD severity by modified National Kidney Foundation staging showed an association of eGFR with vascular events in a dose-dependent manner (Table III in the online-only Data Supplement). In unadjusted analyses, patients with low eGFR were more likely to experience a recurrent stroke (hazard ratio, 1.34; 95% confidence interval, 1.20-1.49). After adjusting for confounders, low eGFR was still associated with recurrent stroke but to a lesser extent (hazard ratio, 1.16; 95% confidence interval, 1.04-1.31). Telmisartan treatment among patients with low eGFR was not independently associated with recurrent stroke (hazard ratio, 1.08; 95% confidence interval, 0.89-1.31).
For the outcome of recurrent stroke, there were no significant 2-way interactions involving telmisartan treatment between eGFR category versus prespecified variables of age, small vessel disease stroke type, and diabetes mellitus.
Discussion
We observed that among patients with a recent ischemic stroke, recurrent stroke risk was significantly higher for those patients with eGFR<60 mL/min than for those patients with higher eGFR values, even after adjusting for potential major confounders. These results suggest that there may be clinical relevance in the use of eGFR in recurrent stroke risk prognostication among patients with recent ischemic stroke. However, unlike results of analyses of patients with cardiac disease, 3 we did not find that add-on treatment with a reninangiotensin modulator was independently related to better clinical outcomes.
The strength of the association between CKD and recurrent stroke risk seems to be less than that reported with primary stroke. 7 This difference may be because of insufficient follow-up period in the current study, or implementation of vascular risk reduction therapies after a primary stroke likely mitigates some of the avenues through which CKD may promote deleterious vascular effects. Multiple explanations have been proposed for the link between CKD and vascular demise, including an enhancement of less conventional vascular risk factors and activation of the RAS by the initial renal endothelial damage with resultant upregulation of inflammatory mediators (cytokines, chemokines, and adhesion molecules) and superoxide scavenging of NO. 8 Meanwhile, the null effect of add-on RAS modulation in the patients with ischemic stroke with CKD in this study might be because of the heterogeneous nature of ischemic stroke, the dose of the agent used, differences among individual RAS modulators. Only a dedicated randomized clinical trial using a RAS modulator in patients with stroke with CKD can clarify this issue properly. Our study is limited because it is a post hoc analysis of a completed randomized trial, these results may not apply to patients whose index stroke is caused by a presumed cardioembolic mechanism, and the follow-up time may have been too brief to see any potentially protective benefits of the RAS modulator. The study was strengthened by the rigorous procedures of the PRoFESS trial design, inclusion of subjects enrolled from around the world and large sample size. 
